Ontunisertib
Ontunisertib is an investigational new drug that is being evaluated by Agomab Spain S.L.U. for the treatment of fibrostenotic Crohn's Disease.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Ontunisertib is an investigational new drug that is being evaluated by Agomab Spain S.L.U. for the treatment of fibrostenotic Crohn's Disease. It is a TGF beta receptor 1 (ALK5) antagonist.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1370060806 under CC BY-SA 4.0; modifications have been made.